2. Critical Parameters of Stability:

Critical parameters refer to the features that directly influence the stability of the product and, consequently, its safety, efficacy and quality. These features encompass chemical composition, temperature, humidity and light exposure²³.

2.1 Temperature:

The Arrhenius equation effectively illustrates how temperature influences the rate constant of degradation reactions, and is expressed as follows:

E₂

K = Ae -----

Where, k= rate constant,

A= pre-exponential factor, Ea= activation energy, R= gas constant, & T=absolute temperature in Kelvin.

Chemical processes can be accelerated by rising temperatures, according to the Arrhenius equation. When it comes to small molecules, heat-sensitive medications may degrade as a result of thermal processing methods like melt extrusion. As an illustration, consider D9-tetrahydrocannabinol (THC), which is especially vulnerable to thermal instability and undergoes substantial degradation when heated. Its stability when added to thermally processed polymer films has been the subject of research. THC's heat stability can be improved and safeguarded by using carriers like polyethylene oxide or hydroxypropyl cellulose in conjunction with antioxidants like ascorbic acid^28-30.

The Arrhenius equation shows how the rate constant k increases with temperature T, which is consistent with the observation that higher temperatures accelerate the degradation of thermally sensitive drugs.

• Degradation Mechanisms:

An increase in temperature can expedite various degradation mechanisms, such as oxidation, hydrolysis, photo-degradation, and isomerization, with each mechanism affecting the drug substance differently.

• Accelerated Stability Testing:

Conditions of temperature stress are implemented to replicate accelerated storage stability in a reduced timespan. By applying higher temperatures (e.g., 40°C or 50°C), the chemical degradation processes are expedited, aiding in the estimation of the product's shelf life under typical conditions.

• Formulation Impact:

Temperature greatly affects formulations with biologics, peptides, and proteins, which are heat-sensitive. Fluctuations can change enzyme activity, protein structure, and compound solubility. Cold denaturation is reversible and less problematic than heat-induced changes. This unique property offers advantages in maintaining protein stability and functionality^31. Temperature during administration, especially with some nebulizers, can cause protein degradation, making temperature control vital for thermolabile drugs. Stability studies often use Arrhenius or modified Arrhenius equations, but these two-step methods have statistical issues recently addressed in the literature. The complexity of these methods, particularly when dealing with proteins and biologics, necessitates careful consideration of their application and potential limitations^33-35.

2.2 Humidity:

Moisture can cause chemical breakdown (like drug hydrolysis), encourage microbial growth, and trigger physical changes such as crystal formation or clumping. A product's hygroscopic nature determines its moisture sensitivity; for example, tablets or powders may absorb moisture, reducing potency or altering structure. In contrast, semi-solids and liquids may undergo notable changes in viscosity and stability when faced with excess moisture.

• Hydrolysis:

Numerous drugs, especially those featuring ester or amide bonds, are susceptible to hydrolysis when subjected to moisture. This reaction has the potential to result in the breakdown of the API, impacting drug effectiveness.

For example: Aspirin (acetylsalicylic acid), which contains an ester functional group, can undergo hydrolysis to yield salicylic acid and acetic acid ^{61, 62} as shown in below.

• Hygroscopicity of Formulations:

Hygroscopic drugs, especially powders, absorb moisture that alters their physical properties. In tablets, moisture can cause softening, swelling, or sticking, affecting integrity, dissolution and drug release, thus reducing efficacy. For example, acetaminophen tablets become sticky in high humidity. In powders like cephalexin, moisture causes clumping, reducing flow and dosing accuracy. In solutions such as ceftriaxone sodium, moisture or calcium exposure can cause harmful precipitates, compromising sterility and bioavailability. To mitigate these issues, moisture-resistant packaging and proper storage conditions, including desiccants and low humidity, are critical for maintaining drug stability.

• Microbial Contamination:

Excessive moisture promotes microbial growth, risking product quality and safety. Formulations without proper moisture barriers may develop harmful bacteria and molds like Enterococcus, Bacillus, Staphylococcus aureus, P. aeruginosa, Salmonella, Aspergillus, Candida, Rhizopus and Alternaria. Maintaining sterile conditions is essential, and manufacturers conduct stability tests at high humidity (e.g., 75% RH) and various temperatures to assess moisture effects and select appropriate packaging.

2.3 Light Exposure:

Certain drugs, especially those in liquid dosage forms, can undergo photo-degradation when subjected to light, particularly ultraviolet (UV) and visible light. This degradation may result in the generation of harmful byproducts and diminished therapeutic effectiveness. Exposure to light is frequently reduced by utilizing opaque or amber containers to shield the product from ultraviolet and visible light. Conducting stability tests under different light scenarios is essential for defining optimal packaging and storage conditions. Photo-degradation can lead to:

• Chemical Degradation:

Active ingredients might degrade when exposed to light, causing a loss of potency and the creation of toxic byproducts. Compounds like Ascorbic acid (Vitamin C) and Riboflavin (Vitamin B2) are particularly at risk for photo-degradation.

• Packaging Considerations:

To lessen light's effect, pharmaceutical products are often stored in opaque or amber packaging that obstructs UV and visible light. This prevents exposure during storage, transport, and use.

• Stability Testing:

Photo-stability tests are conducted to replicate a product's light exposure under specific conditions. The outcomes dictate whether further protective packaging or formulation adjustments are required.

Photo-stability testing simulates light exposure under controlled conditions using UV and visible light to assess a drug's susceptibility to degradation. This helps determine if additional protective measures, such as packaging or formulation adjustments, are needed. For example, paclitaxel, a chemotherapeutic drug, is photolabile and requires strict light protection during storage and administration. According to the ICH Q1B guideline, photo-stability testing identifies if a drug is photolabile or photosensitive, guiding the use of light-resistant packaging (e.g., opaque or amber containers) and appropriate storage conditions to maintain the drug's stability, safety and efficacy⁶³.

2.4 pH:

pH is crucial for drug stability, with neutral pH (like in the small intestine) typically optimal. Deviations toward acidic or alkaline conditions speed degradation due to hydronium or hydroxide ion catalysis. For example, pralidoxime degrades via pH-sensitive pathways, producing toxic cyanide in alkaline conditions, while penicillins break down into allergenic penicillenic acids in acidic (pH ≤2) environments^36,37,38.

pH is vital for API and excipient stability, affecting their integrity, solubility, ionization and reactivity. pH changes can degrade drugs like proteins, peptides, and small molecules. Buffered systems help maintain stable pH in oral, injectable, and topical formulations.

• Effect on API Stability:

The pH influences ionization, solubility and chemical stability. In acidic or basic environments, certain drugs may experience hydrolysis, oxidation, or other degradation forms.

• Buffering Systems:

Buffered solutions are frequently utilized to maintain stability by controlling pH within a desired range. pH variations outside the optimal range can induce instability or reduce therapeutic efficacy. For instance, penicillin solutions are extremely sensitive to pH changes and necessitate a specific pH range for optimal stability.

Evaluating across different pH levels is essential for establishing a drug's stability profile and aids in defining storage conditions, dosage forms, and delivery methods.

2.5. Moisture:

Molecular mobility significantly influences solid-state reactivity. Water acts as a plasticizer, increasing the mobility of the matrix and thereby enhancing the reactivity of its components. To control moisture levels, it is essential to set and monitor moisture content limits for the blend components³⁹. The introduction of water into amorphous molecular-level solid dispersions at room temperature disrupts the drug-polymer interactions irreversibly, causing phase separation between the amorphous components and subsequent crystallization.⁴⁰

2.6. Oxidation of molecules:

Oxidation reactions occur when oxygen is present and are often accelerated by metal ions. Impurities can act as catalysts in autoxidation, promoting the formation of reactive oxygen species, which can be challenging to replicate⁴¹. Force degradation studies for oxidation can be performed in an oxygen-rich environment with peroxides, though using a model incorporating oxygen is typically more representative⁴². To examine the behavior of materials exposed to both heat and oxygen, thermo-oxidative stability is evaluated. Additionally, oxidation reactions can be influenced by light, where photosensitizers absorb light and interact with molecular oxygen to generate highly reactive singlet oxygen species⁴³.

2.7. Excipients:

Excipients can reduce drug stability by reacting chemically within formulations, making compatibility assessment crucial early in development. In melt-extruded formulations, high heat and shear can trigger drug-excipient reactions. During extrusion, the polymer carrier melts, enclosing the drug and excipients. Solubility parameters and drug-polymer miscibility are key to predicting physical stability.

3. Physical parameters of stability:

Physical characteristics are necessary for ensuring stability of pharmaceutical products. These characteristics encompass features such as particle size, viscosity, color and the physical state of the product.

3.1. Particle Size:

The particle size of a solid pharmaceutical ingredient, found in suspensions or powders, can affect its dissolution rate, bioavailability and stability. Smaller particles generally possess a greater surface area, which can enhance the rate of chemical reactions and degradation. Particle size influences the physical stability of suspensions as smaller particles are prone to agglomeration or settling. Thus, regulating the particle size distribution is crucial for sustaining the desired product quality and stability.

• Enhanced Drug Dissolution:

Fine particles dissolve more quickly, which leads to improved bioavailability. However, this may also hasten degradation, particularly when moisture or oxygen is present.

• Physical Stability:

Particle size affects the likelihood of suspensions or emulsions undergoing sedimentation or phase separation. Maintaining a stable particle size distribution is essential for the consistency and effectiveness of suspensions.

• Nanoparticles:

The increasing use of nanotechnology in drug delivery (e.g., nanoparticle-based drug carriers) has presented new considerations for particle size and its effects on both stability and therapeutic activity.

3.2. Viscosity:

Viscosity is key to the stability of liquid formulations like syrups, emulsions and topicals. Changes in viscosity indicate molecular changes, aggregation or component separation. Testing viscosity ensures physical stability and consistent delivery, crucial for injectables where viscosity affects administration ease. It also impacts the formulation's physical stability, with alterations potentially indicating.

• Phase Separation:

An increase or decrease in viscosity may suggest instability, such as the separation of the active ingredient from excipients or the aggregation of particles.

• Ease of Administration:

High-viscosity formulations, like syrups or creams, might necessitate special packaging designs to avoid leakage or damage to the medication during handling.

• Microbial Growth:

Changes in viscosity can signal microbial contamination, particularly in semisolid formulations, and should be monitored throughout stability testing.

3.3. Color and Clarity:

Color changes often signal degradation or contamination in pharmaceuticals, especially parenteral solutions, caused by oxidation or excipient breakdown. Clarity is also crucial for detecting precipitates or aggregates that affect stability. Visual inspections and tools like spectrophotometry assess color and clarity during stability tests. These alterations can be indicative of:

• Chemical Degradation:

Oxidation, polymerization, or other reactions can lead to a product darkening or precipitating, indicating a reduction in potency.

• Clarity:

Suspensions or emulsions may turn cloudy or show visible particles, suggesting instability. For instance, turbidity development in an injectable formulation may render it unsafe for patient use.

4. Evaluating Stability Parameters:

Stability assessment uses accelerated and real-time tests under normal and extreme conditions to evaluate product response to environmental changes. Early-stage accelerated tests identify potential degradation products. The main goal is to ensure products maintain quality and safety throughout their shelf life until use.

4.1. Accelerated Stability Studies:

Accelerated stability testing stores products at high temperature and humidity to speed degradation, helping estimate shelf life and guide formulation. Results need caution as conditions may not mirror real storage. Products are stressed by heat, moisture, light, agitation, pH changes, and packaging, then cooled and analyzed. This rapid testing reduces measurement instability risk versus real-time tests. Furthermore, the comparison between unstressed and stressed samples within the same assay allows for a direct evaluation of recovery, which is expressed as a percentage of the recovery observed in the unstressed samples⁴⁵.

Statistically, accelerated stability testing is recommended at four elevated temperatures. For sensitive or protein-based components, excessive heat should be avoided to prevent denaturation and ensure accurate stability predictions⁴⁶.

4.2. Real-Time Stability Testing:

Real-time stability testing monitors product degradation over an extended period under recommended storage conditions, ensuring changes are distinct from normal assay variations. Testing duration depends on the product’s stability and allows trend analysis by collecting data at set intervals. It also assesses reference material stability, reagent consistency and instrument performance to detect any system drift. Conducted over the full shelf life under standard conditions, this method reliably determines actual product shelf life by periodically evaluating critical physical and chemical parameters.

4.3. Retained sample stability testing:

Stability data is mandatory for all marketed products. Samples are usually retained from at least one batch annually. For over 50 batches marketed, samples from two batches are recommended. Initially, samples from each batch may be collected but later reduced to 2–5% of batches. Samples are tested at set intervals—commonly at 3, 6, 9, 12, 18, 24, 36, 48, and 60 months for a five-year shelf life.

4.4. Cyclic temperature stress testing:

Cyclic temperature stress testing is designed to simulate temperature fluctuations pharmaceuticals may encounter during storage, often using 24hour cycles reflecting the Earth's diurnal rhythm. The specific minimum and maximum temperatures for these cycles are determined case-by-case, based on the product’s recommended storage conditions and its unique chemical and physical stability characteristics. Typically, this test involves about 20 cycles to assess product stability under realistic fluctuating temperature conditions. This approach helps predict how the product will behave in real-market scenarios and supports formulation optimization and packaging decisions. It is generally recommended that the test consist of 20 cycles to adequately assess the product's stability under these conditions⁴⁸.

5. Role of Packaging in Stability:

Pharmaceutical products are tested in their intended market container and closure systems, including primary packaging like aluminum strip packs, HDPE bottles, blister packs and Alu-Alu packs. Secondary packaging may be included but excludes shipping containers. All products—distribution, physician or promotional samples—require testing per container type. Bulk containers may use prototype packaging if closely resembling final versions.

Container orientation during stability testing (upright, inverted, or sideways) is crucial, especially for solutions, dispersions, and semi-solids, to detect interactions such as substance extraction from closures or product adsorption into packaging. Packaging protects the product from external factors like moisture, oxygen and light, preserving drug stability and physical properties such as viscosity and preventing contamination. Packaging choice depends on drug properties, environmental sensitivity and shelf life requirements, playing a key role in maintaining product quality throughout storage and use.

• Barrier Properties:

Materials like aluminum, amber glass and foil pouches are commonly utilized to create an effective barrier against light and moisture.

• Interactive Packaging:

Contemporary packaging systems, such as desiccants or oxygen scavengers, provide active protection for the formulation against environmental influences.

• Regulatory Standards:

Packaging must adhere to strict regulatory standards, ensuring that it is functional and complies with safety regulations.

6. Regulatory Considerations:

Regulatory authorities such as the U.S. FDA and the European Medicines Agency (EMA) set comprehensive guidelines for the stability testing of pharmaceutical products. These guidelines define the required testing procedures, storage conditions, and reporting standards to ensure that drug products maintain their intended quality throughout their shelf life. Stability testing data is essential for obtaining regulatory approval and maintaining the product's market authorization.

6.1. Overview of ICH Guidelines and Their Regulatory Framework**:

ICH has successfully harmonized quality aspects including stability studies and impurity testing thresholds, with its guidelines widely adopted by regulatory authorities in ICH regions. These guidelines emphasize the importance of forced degradation studies but provide only broad recommendations on experimental stress conditions without detailed guidance on specific parameters like pH, temperature, or oxidizing agents to use. Hence, while the ICH guidelines set the framework for conducting stability and forced degradation studies, detailed experimental conditions are left to the discretion of the applicant, guided by scientific judgment and product-specific considerations.

The ICH guidelines related to forced degradation studies are as follows:

• ICH Q1A – Stability Testing of New Drug Substances and Products (ICH Expert Working Group, 2003a)⁵¹

• ICH Q1B – Photostability Evaluation of New Drug Substances and Products (ICH, 2003b)⁵²

• ICH Q2B – Confirmation of Analytical Procedures: Methodology (ICH, 1996a)⁵³

• ICH Q3A – Contaminants in New Drug Substances (ICH Harmonised Tripartite Guideline, 2006a)⁵⁴

• ICH Q3B – Contaminants in New Products (ICH Harmonised Tripartite Guideline, 2006b)⁵⁵

• ICH M4Q (R1) – The standard Technical Document (CTD): Quality (ICH Harmonised Tripartite Guideline, 2002)⁵⁶

The ICH Q1A guideline defines stress testing of drug substances as investigations conducted to evaluate the inherent stability of drugs under more extreme conditions than typical accelerated conditions. These stress tests are considered part of the development strategy and are designed to identify potential degradation impurities, understand the degradation mechanisms and assess the intrinsic stability of the drugs (ICH Expert Working Group, 2003). The guideline provides general recommendations for conducting stress tests when deemed appropriate. Concerning degradation products formed during stress testing, it is suggested that the examination of specific degradation products may not be necessary if their formation is unlikely under accelerated or long-term storage conditions (ICH Expert Working Group, 2003).

The ICH Q1B guideline focuses on photostability testing for new drugs and their formulations. It distinguishes between stress testing, which intentionally degrades drugs and confirmatory testing, which evaluates drug stability under standard storage conditions. Confirmatory testing helps establish guidelines for manufacturing precautions, such as packaging materials and labeling instructions. The procedure for selecting batches for confirmatory studies should align with the protocols recommended for long-term and accelerated stability studies in the original guideline. The goal of photolytic stress studies is to evaluate the photosensitivity of the drug, assisting in the development of analytical methods and understanding degradation mechanisms. Forced degradation studies are essential for developing and validating stability-indicating methods needed for analyzing real-time stability samples. The guideline provides recommendations on approaches to assess the photostability of drugs and their formulations in the context of developing these analytical methods (ICH, 2003a). If a photostability study is prematurely terminated due to excessive degradation, scientific justification is required (ICH, 2003a). Photostability testing is applicable to solids, solutions and suspensions. Stress testing should be designed to provide sufficient data for the development and validation of analytical methods used in confirmatory studies, capable of identifying potential photolytic degradation products ⁵⁷. Similar to the Q1A guideline, the Q1B guideline also suggests that forced degradation products may not be observed during routine stability studies. However, these products are critical for developing and validating analytical methods, and their characterization may not be necessary if they do not form under routine stability conditions (ICH, 2003a; ICH Expert Working Group, 2003).

The ICH Q2B guideline offers recommendations on the validation of analytical methods, advising the use of samples from stress testing under various conditions, including light, heat, humidity, acid/base hydrolysis and oxidation. This ensures the specificity of the method, especially when standards for impurities or degradation products are unavailable. The guideline emphasizes the need to establish the distinctiveness of analytical methods to accurately analyze the analyte in the presence of other substances, such as impurities or degradation products (ICH, 1996a).

The ICH Q3A (2006a) and Q3B (2006b) guidelines recommend identifying each impurity during stability testing. If an impurity cannot be identified, a summary of failed identification attempts should be provided. The Q3B guideline also requires that analytical methods be validated for selectivity, ensuring they can distinguish between specific and non-specific degradants. Samples subjected to appropriate forced degradation conditions should be used to validate these methods (ICH, 2006b).

According to the ICH M4Q (R1) guideline (2002), the stability study summary should include detailed information on study types, protocols, and results. Data from forced degradation studies, including the conditions applied and storage recommendations (such as retest periods and shelf life), must be presented in the summary. Stability data should be formatted appropriately, whether in tabular, graphic, or narrative form. Details regarding the analytical method and its validation process must also be included (ICH, 2002)⁵⁷.

6.2. European Medicines Agency (EMA)

The European Medicines Agency (EMA) guidelines require that stress testing studies clearly summarize study types, protocols and results. Documentation must detail stress conditions, outcomes, and recommendations on storage, retest, or expiration dates. Guideline 15 states that if a drug appears in an official pharmacopoeial monograph, degradation product data aren't required; instead, degradation pathways can be supported by scientific literature. This ensures clarity and regulatory compliance while reducing unnecessary testing. However, if such data is unavailable in the literature or pharmacopoeias, a forced degradation study must be performed⁵⁸.

The EMA guideline for investigational drugs in clinical trials emphasizes establishing key stability parameters such as physicochemical sensitivity, photosensitivity and hygroscopicity, along with describing potential degradation mechanisms. It recommends designing the stability protocol based on existing knowledge and experience with the active pharmaceutical ingredients and their final formulations, ensuring a science-driven and risk-based approach to stability evaluation. All available information on stability and forced degradation profiles should be incorporated into the design of the stability testing⁵⁹.

6.3. FDA guidelines and its regulatory overview:

According to FDA guidelines, forced degradation studies are conducted during drug development to deliberately degrade the drug substance or product. These studies help assess photosensitivity, understand degradation mechanisms, and aid in developing analytical methods. The FDA differentiates stress studies (to evaluate photosensitivity and degradation pathways) from confirmatory studies. Forced degradation testing is primarily used to evaluate photosensitivity and establish degradation pathways, supporting method development and validation. Additionally, forced degradation studies are also valuable for validating analytical methods by applying various stress conditions^60,61.

7. CONCLUSION:

The stability of pharmaceutical products is vital for ensuring their safety, efficacy, and overall therapeutic effectiveness throughout their shelf life. Grasping and managing the critical and physical parameters that affect drug stability is crucial for the development of safe and reliable pharmaceutical products. This review underscores the significant influence of factors such as temperature, humidity, light exposure, pH, particle size, viscosity and color on the chemical, physical, and microbial stability of drug formulations. Temperature and humidity, two of the most significant factors, can hasten degradation processes, including hydrolysis, oxidation, and photo-degradation, which may lead to decreased potency and the generation of harmful byproducts. The role of pH in preserving optimal solubility and stability is paramount, especially for liquid formulations. Likewise, physical parameters such as particle size and viscosity influence the dissolution rate, bioavailability, and uniformity of the drug product, directly impacting its stability and patient outcomes. Alterations in physical characteristics, such as color and clarity, can signal early signs of product instability or degradation. Stability testing, whether accelerated or real-time, is vital for estimating a drug product’s shelf life and ensuring adherence to regulatory standards. Utilizing suitable packaging, which shields the drug from environmental factors such as moisture and light, additionally aids in preserving product integrity. Following established regulatory guidelines, like those from the ICH and FDA, guarantees that stability testing is performed in a uniform and thorough way, ultimately protecting public health.

In conclusion, stability is not merely a technical issue but a vital aspect of pharmaceutical development. By meticulously evaluating and managing the critical and physical parameters of stability, manufacturers can confirm that their products continue to be safe, effective, and dependable throughout their intended shelf life. This thorough comprehension of stability factors is crucial for progressing the field of pharmaceutical sciences and providing high-quality medications to patients globally.

8. ACKNOWLEDGEMENTS:

We would like to express our sincere gratitude to the Zuventus Healthcare Ltd. We acknowledge with gratitude all those who have contributed directly or indirectly to the completion of this review paper. Your collective efforts have been integral to its success, and we are deeply appreciative of your contributions.

10. DATA AVAILABILITY:

Data will be made available on request.

11. CONFLICT OF INTEREST:

The authors declare no conflict of interest.

12. CONSENT FOR PUBLICATION:

All authors have approved the manuscript for publication.

13. REFERENCES:

1. Shaikh RH, Sial AA. Stability of pharmaceutical formulations. Pak. J. Pharma. Sci. 1996: 83-6.

2. Guo Y, Shalaev E, Smith S. Physical stability of pharmaceutical formulations: solid-state characterization of amorphous dispersions. TrAC Trends in Analytical Chemistry. 2013 Sep 1; 49: 137-44.

3. Huynh-Ba K. Handbook of stability testing in pharmaceutical development: regulations, methodologies, and best practices. New York: Springer; 2009.

4. Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Molecular Diversity. 2021 Aug; 25: 1315-60.

5. Kerketta GS. A crucial component of pharmaceutical quality as-surance is drug Stability Testing.

6. Chavda H. In-use stability studies: guidelines and challenges. Drug Development and Industrial Pharmacy. 2021 Sep 2; 47(9): 1373-91.

7. Rignall A. ICHQ1A (R2) Stability testing of new drug substance and product and ICHQ1C stability testing of new dosage forms. ICH Quality Guidelines: An Implementation Guide. 2017 Sep 27:3-44.

8. Ahmad B, Imran M. Emerging Organic Contaminants, Pharmaceuticals and Personal Care Products (PPCPs): A Threat to Water Quality. In Hazardous Environmental Micro-pollutants, Health Impacts and Allied Treatment Technologies 2022 Jun 28 (pp. 105-141). Cham: Springer International Publishing.

9. Lachman L, Lieberman HA, Kanig JL. The Theory and Practice of Industrial Pharmacy. Philadelphia: Lea & Febiger; 1976.

10. Chavda H. In-use stability studies: Guidelines and Challenges. Drug Development and Industrial Pharmacy. 2021 Sep 2; 47(9):1373-91.

11. Kohn, J., & Yei, M. (2015). The effect of temperature on the stability of drug products: The Arrhenius model. Pharmaceutical Development and Technology, 20(1), 1-11

12. Taylor MJ, Weegman BP, Baicu SC, Giwa SE. New approaches to cryopreservation of cells, tissues, and organs. Transfusion Medicine and Hemotherapy. 2019 Jun 4; 46(3):197-215.

13. Macías FA, Mejías FJ, Molinillo JM. Recent advances in allelopathy for weed control: from knowledge to applications. Pest Management Science. 2019 Sep; 75(9):2413-36.

14. Guideline IH. Stability testing of new drug substances and products. Q1A (R2), Current Step. 2003 Feb; 4(1-24).

15. Chaurasia G. A review on pharmaceutical preformulation studies in formulation and development of new drug molecules. Int J Pharm Sci Res. 2016 Jun 1; 7(6):2313-20.

16. Blessy MR, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs—A review. Journal of Pharmaceutical Analysis. 2014 Jun 1; 4(3):159-65.

17. Thorat P, Warad S, Solunke R, Sargar A, Bhujbal A, Shinde A. Stability study of dosage form: an innovative step. World J Pharm Pharm Sci. 2014; 3(2):1031-50.

18. Freed AL, Colgan ST, Kochling JD, Alasandro MS. Accelerating pharmaceutical development through predictive stability approaches. AAPS J. 2017; 3:2-10.

19. Thakor KA, Bhavsar DD, Thakor JR. A review article–development of forced degradation and stability indicating studies for drug substance and drug product. International Journal of Research in Pharmacology and Pharmacotherapeutics. 2016; 5(4): 291-97.

20. Rajveer B, Monika O, Agnihotri V, Arjun C, Harpalsing G. Current trend in performance of forced degradation studies for drug substance and drug products. Journal of Drug Delivery and Therapeutics. 2020; 10:149-55.

21. Narayan S, Choudhary M. A review on stability studies of pharmaceutical products. International Journal of Applied Pharmaceutical and Biological Research. 2017; 2(3):67-75.

22. Agarwal V, Sharma D. Stability testing of active pharmaceutical and scientific innovation. J Pharm Sci Innov. 2012; 1:18-23. Passi I, Salwan S, Kumar B. US-FDA approved drugs in 2020 and 2021: a review. Mini Reviews in Medicinal Chemistry. 2023 Jul 1; 23(12):1273-97.

23. Ware LB, Matthay MA. The Acute Respiratory Distress Syndrome. N Engl J Med. 2000 May 4; 342(18):1334–49.)

24. Williams III RO, Idell S. Compositions and methods for administration of an enzyme to a subject’s airway. WO2015066664 A2, 2015.

25. Stringer KA, Dunn JS, Gustafson DL. Administration of exogenous tissue plasminogen activator reduces oedema in mice lacking the tissue plasminogen activator gene. Clinical and Experimental Pharmacology and Physiology. 2004 May; 31(5‐6):327-30.

26. Stringer KA, Tobias M, Dunn JS, Campos J, Van Rheen Z, Mosharraf M, et al. Accelerated Dosing Frequency of a Pulmonary Formulation of Tissue Plasminogen Activator is Well-Tolerated in Mice. Clin Exp Pharmacol Physiol. 2008; 35(12):1454–60.).

27. Munjal M, Stodghill SP, ElSohly MA, Repka MA. Polymeric systems for amorphous Δ9-tetrahydrocannabinol produced by a hot-melt method. Part I: Chemical and thermal stability during processing. Journal of Pharmaceutical Sciences. 2006 Aug 1; 95(8):1841-53.

28. Munjal M, ElSohly MA, Repka MA. Chemical stabilization of a Δ 9-tetrahydrocannabinol prodrug in polymeric matrix systems produced by a hot-melt method: Role of Microenvironment pH. AAPs Pharmscitech. 2006 Sep; 7: E114-25.

29. Munjal M, ElSohly MA, Repka MA. Polymeric systems for amorphous Δ9-tetrahydrocannabinol produced by a hot-melt method. Part II: Effect of oxidation mechanisms and chemical interactions on stability. Journal of Pharmaceutical Sciences. 2006 Nov 1; 95(11):2473-85.

30. Franks F. Protein destabilization at low temperatures. Advances in Protein Chemistry. 1995 Jan 1; 46:105-39.

31. Hertel S, Pohl T, Friess W, Winter G. That’s cool! –Nebulization of thermolabile proteins with a cooled vibrating mesh nebulizer. European Journal of Pharmaceutics and Biopharmaceutics. 2014 Jul 1; 87(2):357-65.

32. Bentley DL. Statistical techniques in predicting thermal stability. Journal of Pharmaceutical Sciences. 1970 Apr 1; 59(4):464-8.

33. Davies OL, Hudson HE. Stability of drugs: accelerated storage tests. Statistics in the Pharmaceutical Industry. 1981:355-95.

34. King SY, Kung MS, Fung HL. Statistical prediction of drug stability based on nonlinear parameter estimation. Journal of Pharmaceutical Sciences. 1984 May 1; 73(5):657-62.

35. Yoshioka S, Stella VJ. Stability of drugs and dosage forms. Springer Science & Business Media; 2000 Dec 31.

36. Ellin RI, Wills JH. Oximes Antagonistic to Inhibitors of Cholinesterase: Part I. Journal of Pharmaceutical Sciences. 1964 Sep 1; 53(9):995-1007.

37. Deshpande AD, Baheti KG, Chatterjee NR. Degradation of β-lactam antibiotics. Current Science. 2004 Dec 25:1684-95.

38. Hengsawas S. Importance of Stability of Pharmaceutical Formulations (Doctoral Dissertation).

39. Marsac PJ, Rumondor AC, Nivens DE, Kestur US, Stanciu L, Taylor LS. Effect of temperature and moisture on the miscibility of amorphous dispersions of felodipine and poly (vinyl pyrrolidone). Journal of Pharmaceutical Sciences. 2010 Jan 1; 99(1):169-85.

40. Harmon P, Boccardi G. Oxidative susceptibility testing. In Pharmaceutical Stress Testing 2016 Apr 19 (pp. 180-203). CRC Press.

41. Alsante KM, Ando A, Brown R, Ensing J, Hatajik TD, Kong W, Tsuda Y. The role of degradant profiling in active pharmaceutical ingredients and drug products. Advanced Drug Delivery Reviews. 2007 Jan 10; 59(1): 29-37.

42. Camacho W, Karlsson S. Assessment of thermal and thermo-oxidative stability of multi-extruded recycled PP, HDPE and a blend thereof. Polymer Degradation and Stability. 2002 Jan 1; 78(2):385-91.

43. Bruce CD. Recrystallization of guaifenesin from hot-melt extrudates containing Acryl-EZE or Eudragit L100-55. The University of Texas at Austin; 2008.

44. Kommanaboyina B. Regulation of Stability of Marketed Pharmaceuticals.

45. Anderson JR. The adaptive nature of human categorization. Psychological Review. 1991 Jul; 98(3):409.

46. Bajaj S, Singla D, Sakhuja N. Stability testing of pharmaceutical products. Journal of Applied Pharmaceutical Science. 2012 Mar 30(Issue):129-38.

47. Carstensen JT. Drug Stability: Principles and Practices. (No Title). 1995 Jan.

48. Bakshi M, Singh S. Development of validated stability-indicating assay methods—critical review. Journal of pharmaceutical and biomedical analysis. 2002 Jun 15; 28(6):1011-40.

49. Ali J, Khar RK, Ahuja A. Dosage Form and Design. CBS Publishers and Distributers. Delhi. 2008; 1:2004-05.

50. Clapham D. Stability Testing: Photostability Testing of New Drug Substances and Products ICH Q1B. ICH Quality Guidelines: An Implementation Guide. 2017 Sep 27:45-72.

51. Khan H, Ali M, Ahuja A, Ali J. Stability testing of pharmaceutical products-comparison of stability testing guidelines. Current Pharmaceutical Analysis. 2010 May 1; 6(2):142-50.

52. ICH T. Guidance for industry: Q2B validation of analytical procedures: Methodology. Food and Drug Administration, Centre for Drug Evaluation and Research, Centre for Biologics Evaluation and Research. 1996; 1269.

53. Guideline IH. Impurities in new drug substances Q3A (R2). In Proceedings of the international conference on harmonization of technical requirements for registration of pharmaceuticals for human use, Geneva, Switzerland 2006 Oct 25 (Vol. 25).

54. Guideline IH. Impurities in New Drug Products. Q3B (R2), Current Step. 2006 Jun; 4:1-5.

55. Guideline IH. Evaluation for Stability Data. ICH Q1E. ICH. 2003 Feb; 6:1-9.

56. Iram F, Iram H, Iqbal AZ, Husain A. Forced degradation studies. Journal of Analytical & Pharmaceutical Research. 2016; 3(6):73.

57. Committee for Medicinal Products for Human Use. Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials. London, UK: European Medicines Agency. 2012.

58. Committee for Medicinal Products for Human Use. European Medicines Agency (2006). Guideline on the Limits of Genotoxic impurities. EMEA/CHMP/QWP/251344; 2006.

59. Guideline IH. Photostability testing of new drug substance and products. Fed. Register. 1996; 62:27115-22.

60. Nunes JC, Cristóvão RO, Freire MG, Santos-Ebinuma VC, Faria JL, Silva CG, Tavares AP. Recent strategies and applications for L-asparaginase confinement. Molecules. 2020 Dec 10; 25(24):5827.

61. Croxall MP, Lawrence RT, Goh MC. 1H NMR as a quick screen for photocatalytic reaction efficiency. Journal of Photochemistry and Photobiology A: Chemistry. 2019 Sep 1; 382:111965.

Received on 23.05.2025 Revised on 06.08.2025

Accepted on 17.09.2025 Published on 27.01.2026

Available online from February 02, 2026

Asian Journal of Pharmaceutical Analysis. 2026; 16(1):41-50.

DOI: 10.52711/2231-5675.2026.00007

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.